par Saini, Kamal 
;Punie, Kevin;Twelves, Chris;Bortini, Stefanella;de Azambuja, Evandro ;Anderson, Steven;Criscitiello, Carmen ;Awada, Ahmad ;Loi, Sherene
Référence Expert opinion on biological therapy, 21, 7, page (945-962)
Publication Publié, 2021-12-01
;Punie, Kevin;Twelves, Chris;Bortini, Stefanella;de Azambuja, Evandro ;Anderson, Steven;Criscitiello, Carmen ;Awada, Ahmad ;Loi, Sherene Référence Expert opinion on biological therapy, 21, 7, page (945-962)
Publication Publié, 2021-12-01
Article révisé par les pairs
| Titre: |
|
| Auteur: | Saini, Kamal; Punie, Kevin; Twelves, Chris; Bortini, Stefanella; de Azambuja, Evandro; Anderson, Steven; Criscitiello, Carmen; Awada, Ahmad; Loi, Sherene |
| Informations sur la publication: | Expert opinion on biological therapy, 21, 7, page (945-962) |
| Statut de publication: | Publié, 2021-12-01 |
| Sujet CREF: | Pharmacologie |
| Médecine clinique [chimie clinique] | |
| Mots-clés: | antibody–drug conjugate |
| atezolizumab | |
| Breast cancer | |
| bystander effect | |
| dual therapy | |
| immune checkpoint inhibitor | |
| pembrolizumab | |
| sacituzumab govitecan | |
| trastuzumab deruxtecan | |
| trastuzumab emtansine | |
| Note générale: | SCOPUS: ar.j |
| Langue: | Anglais |
| Identificateurs: | urn:issn:1471-2598 |
| info:doi/10.1080/14712598.2021.1936494 | |
| info:scp/85107934071 | |
| info:pmid/34043927 |
